[The clinical use of the new antioxidant thiotriazoline in ischemic ophthalmopathies].
The new antioxidant Thiotriazoline was used in the treatment of patients with retinal vascular occlusive processes. The agent improved retinal metabolism by inhibiting free radical oxidation. Thiotriazoline is superior to alpha-tocopherol acetate in its activity. Unlike the latter, it has no vasodilating effect.